vs

Side-by-side financial comparison of CARPENTER TECHNOLOGY CORP (CRS) and ResMed (RMD). Click either name above to swap in a different company.

ResMed is the larger business by last-quarter revenue ($1.4B vs $811.5M, roughly 1.8× CARPENTER TECHNOLOGY CORP). ResMed runs the higher net margin — 27.6% vs 17.2%, a 10.4% gap on every dollar of revenue. On growth, CARPENTER TECHNOLOGY CORP posted the faster year-over-year revenue change (11.6% vs 11.0%). Over the past eight quarters, ResMed's revenue compounded faster (7.9% CAGR vs 0.8%).

Carpenter Technology Corporation develops, manufactures, and distributes stainless steels and corrosion-resistant nickel, copper and titanium alloys as well as powdered alloys for 3D additive manufacturing. In fiscal year 2018, the company's revenues were derived from the aerospace and defense industry (55%), the industrial and consumer industry (17%), the medical industry (8%), the transportation industry (7%), the energy industry (7%), and the distribution industry (6%). The company's produ...

ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19.

CRS vs RMD — Head-to-Head

Bigger by revenue
RMD
RMD
1.8× larger
RMD
$1.4B
$811.5M
CRS
Growing faster (revenue YoY)
CRS
CRS
+0.6% gap
CRS
11.6%
11.0%
RMD
Higher net margin
RMD
RMD
10.4% more per $
RMD
27.6%
17.2%
CRS
Faster 2-yr revenue CAGR
RMD
RMD
Annualised
RMD
7.9%
0.8%
CRS

Income Statement — Q3 FY2026 vs Q4 FY2026

Metric
CRS
CRS
RMD
RMD
Revenue
$811.5M
$1.4B
Net Profit
$139.6M
$392.6M
Gross Margin
31.0%
61.8%
Operating Margin
23.0%
34.6%
Net Margin
17.2%
27.6%
Revenue YoY
11.6%
11.0%
Net Profit YoY
46.3%
13.9%
EPS (diluted)
$2.77
$2.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRS
CRS
RMD
RMD
Q2 26
$1.4B
Q1 26
$811.5M
Q4 25
$728.0M
$1.4B
Q3 25
$733.7M
$1.3B
Q2 25
$755.6M
$1.3B
Q1 25
$727.0M
$1.3B
Q4 24
$676.9M
$1.3B
Q3 24
$717.6M
$1.2B
Net Profit
CRS
CRS
RMD
RMD
Q2 26
$392.6M
Q1 26
$139.6M
Q4 25
$105.3M
$392.6M
Q3 25
$122.5M
$348.5M
Q2 25
$111.7M
$379.7M
Q1 25
$95.4M
$365.0M
Q4 24
$84.1M
$344.6M
Q3 24
$84.8M
$311.4M
Gross Margin
CRS
CRS
RMD
RMD
Q2 26
61.8%
Q1 26
31.0%
Q4 25
30.0%
61.8%
Q3 25
29.5%
61.5%
Q2 25
28.3%
60.8%
Q1 25
27.6%
59.3%
Q4 24
26.2%
58.6%
Q3 24
24.6%
58.6%
Operating Margin
CRS
CRS
RMD
RMD
Q2 26
34.6%
Q1 26
23.0%
Q4 25
21.3%
34.6%
Q3 25
20.9%
33.4%
Q2 25
20.1%
33.7%
Q1 25
19.0%
33.0%
Q4 24
17.6%
32.5%
Q3 24
15.8%
31.6%
Net Margin
CRS
CRS
RMD
RMD
Q2 26
27.6%
Q1 26
17.2%
Q4 25
14.5%
27.6%
Q3 25
16.7%
26.1%
Q2 25
14.8%
28.2%
Q1 25
13.1%
28.3%
Q4 24
12.4%
26.9%
Q3 24
11.8%
25.4%
EPS (diluted)
CRS
CRS
RMD
RMD
Q2 26
$2.68
Q1 26
$2.77
Q4 25
$2.09
$2.68
Q3 25
$2.43
$2.37
Q2 25
$2.21
$2.58
Q1 25
$1.88
$2.48
Q4 24
$1.66
$2.34
Q3 24
$1.67
$2.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRS
CRS
RMD
RMD
Cash + ST InvestmentsLiquidity on hand
$294.8M
$1.4B
Total DebtLower is stronger
$690.4M
$663.8M
Stockholders' EquityBook value
$2.1B
$6.3B
Total Assets
$3.7B
$8.5B
Debt / EquityLower = less leverage
0.33×
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRS
CRS
RMD
RMD
Q2 26
$1.4B
Q1 26
$294.8M
Q4 25
$231.9M
$1.4B
Q3 25
$208.0M
$1.4B
Q2 25
$315.5M
$1.2B
Q1 25
$151.5M
$932.7M
Q4 24
$162.1M
$521.9M
Q3 24
$150.2M
$426.4M
Total Debt
CRS
CRS
RMD
RMD
Q2 26
$663.8M
Q1 26
$690.4M
Q4 25
$403.9M
Q3 25
$408.7M
Q2 25
$658.4M
Q1 25
$663.1M
Q4 24
$662.9M
Q3 24
$667.6M
Stockholders' Equity
CRS
CRS
RMD
RMD
Q2 26
$6.3B
Q1 26
$2.1B
Q4 25
$2.0B
$6.3B
Q3 25
$1.9B
$6.1B
Q2 25
$1.9B
$6.0B
Q1 25
$1.8B
$5.5B
Q4 24
$1.7B
$5.3B
Q3 24
$1.7B
$5.2B
Total Assets
CRS
CRS
RMD
RMD
Q2 26
$8.5B
Q1 26
$3.7B
Q4 25
$3.5B
$8.5B
Q3 25
$3.4B
$8.3B
Q2 25
$3.5B
$8.2B
Q1 25
$3.4B
$7.6B
Q4 24
$3.3B
$7.1B
Q3 24
$3.3B
$7.2B
Debt / Equity
CRS
CRS
RMD
RMD
Q2 26
0.11×
Q1 26
0.33×
Q4 25
0.06×
Q3 25
0.07×
Q2 25
0.11×
Q1 25
0.12×
Q4 24
0.13×
Q3 24
0.13×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRS
CRS
RMD
RMD
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$124.8M
FCF MarginFCF / Revenue
15.4%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$407.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRS
CRS
RMD
RMD
Q2 26
Q1 26
Q4 25
$132.2M
$339.7M
Q3 25
$39.2M
$457.3M
Q2 25
$258.1M
$538.8M
Q1 25
$74.2M
$578.7M
Q4 24
$67.9M
$308.6M
Q3 24
$40.2M
$325.5M
Free Cash Flow
CRS
CRS
RMD
RMD
Q2 26
Q1 26
$124.8M
Q4 25
$85.9M
$311.2M
Q3 25
$-3.4M
$414.4M
Q2 25
$200.2M
$508.2M
Q1 25
$34.0M
$557.9M
Q4 24
$38.6M
$288.0M
Q3 24
$13.3M
$307.7M
FCF Margin
CRS
CRS
RMD
RMD
Q2 26
Q1 26
15.4%
Q4 25
11.8%
21.9%
Q3 25
-0.5%
31.0%
Q2 25
26.5%
37.7%
Q1 25
4.7%
43.2%
Q4 24
5.7%
22.5%
Q3 24
1.9%
25.1%
Capex Intensity
CRS
CRS
RMD
RMD
Q2 26
Q1 26
Q4 25
6.4%
2.0%
Q3 25
5.8%
3.2%
Q2 25
7.7%
2.3%
Q1 25
5.5%
1.6%
Q4 24
4.3%
1.6%
Q3 24
3.7%
1.5%
Cash Conversion
CRS
CRS
RMD
RMD
Q2 26
Q1 26
Q4 25
1.26×
0.87×
Q3 25
0.32×
1.31×
Q2 25
2.31×
1.42×
Q1 25
0.78×
1.59×
Q4 24
0.81×
0.90×
Q3 24
0.47×
1.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRS
CRS

Aerospace and Defense$435.6M54%
Surcharge revenue$155.9M19%
Industrial and Consumer$78.1M10%
Medical$51.7M6%
Energy$50.5M6%
Distribution$20.4M3%
Transportation$19.3M2%

RMD
RMD

Segment breakdown not available.

Related Comparisons